Topics
Latest
AI
Amazon
Image Credits:Eugene Gologursky/The New York Times / Getty Images
Apps
Biotech & Health
mood
Image Credits:Eugene Gologursky/The New York Times / Getty Images
Cloud Computing
Commerce
Crypto
go-ahead
EVs
Fintech
Fundraising
contraption
bet on
Government & Policy
Hardware
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
societal
quad
Startups
TikTok
conveyance
Venture
More from TechCrunch
event
Startup Battlefield
StrictlyVC
newssheet
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
OpenAI CEO Sam Altman is doubling down onRetro Biosciences , a biotech startup based in San Francisco that wants humans to live 10 class longer than what it calls a healthy human lifespan .
Altman previouslyprovidedRetro Biosciences ’ entire seed round of $ 180 million . Now , the inauguration is raising a $ 1 billion Series A that Altman is joining , the Financial Timesreports .
Retro Biosciences , which say it contrive to set in motion trial for drugs targeting disease like Alzheimer ’s , recentlytrained a modelwith OpenAI to turn veritable cells into base cells .
CEO Joe Betts - LaCroix told the FT he wants to move fast by discovering and developing a drug “ in the 2020s . ”
The startup joins other major billionaire - backed length of service travail , include Altos Labs , whichlaunchedwith $ 3 billion in 2022 backed by Jeff Bezos , and Unity Biotechnology , supportedby both Bezos and Peter Thiel .
